Healius shares slump 23pc as rising costs hit pathology giant with no relief from federal budget

Pathology operator Healius (ASX: HLS) has downgraded its full-year earnings guidance and warned that charging patients out-of-pocket fees for pathology tests is now the only viable option to bridge a widening funding gap, as the federal budget delivered no new support for the sector and a Fair…


Click here to view the original article.